VEGFA and macular retinal edema: A recent meta-analysis showed that while all anti-VEGF agents (aflibercept 2 mg, bevacizumab, faricimab, and ranibizumab) are effective for RVO-induced macular edema, faricimab demonstrated the highest improvement in BCVA, with a pooled result of 16.9 (95% CI: 8.794 to 25.006, p < 0.001), reflecting the best efficacy in the study (Chen et al., 2025).